NivolumabGrade 3 Hepatitis and grade 4 colitis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2032卷 / 1期

关键词：

D O I：

10.1007/s40278-024-70027-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：366 / 366

相关论文

共 50 条

[1] NivolumabGrade 3 nephritis, grade 3 myocarditis and grade 4 pneumonitis: 3 case reports
Reactions Weekly, 2025, 2040 (1) : 750 - 750
[2] NivolumabGrade 2 pneumonitis: 3 case reports
Reactions Weekly, 2017, 1681 (1) : 266 - 266
[3] NivolumabGrade 2 pneumonitis : 3 case reports
Reactions Weekly, 2017, 1659 (1) : 216 - 216
[4] Ipilimumab/nivolumabGrade 3 colitis: case report
Reactions Weekly, 2023, 1986 (1) : 222 - 222
[5] Ipilimumab/nivolumab/NivolumabGrade 3 haemorrhagic gastritis and grade 3 hepatitis: case report
Reactions Weekly, 2025, 2040 (1) : 497 - 497
[6] PembrolizumabGrade 3 hepatitis, grade 2 colitis, grade 1 thyroiditis and off-label use: 6 case reports
Reactions Weekly, 2022, 1887 (1) : 567 - 567
[7] Ipilimumab/nivolumabGrade 3 autoimmune hepatitis: case report
Reactions Weekly, 2022, 1929 (1) : 359 - 359
[8] NivolumabGrade 5 colitis: case report
Reactions Weekly, 2020, 1822 (1) : 232 - 232
[9] Durvalumab/ipilimumab/nivolumabGrade 5 pneumonitis: 2 case reports
Reactions Weekly, 2021, 1871 (1) : 155 - 155
[10] NivolumabGrade 3 immune-related hepatitis: case report
Reactions Weekly, 2018, 1709 (1) : 185 - 185

← 1 2 3 4 5 →